Contraceptive Patch Should Stay, But With Stronger Labeling, REMS

Devices & Diagnostics Letter
A joint FDA advisory panel is recommending Janssen Pharmaceuticals’ Ortho Evra transdermal contraceptive patch remain on the market as its benefits outweigh the risk of blood clots for most women.

To View This Article:


Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00